| __timestamp | Agios Pharmaceuticals, Inc. | Amgen Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 4699000000 |
| Thursday, January 1, 2015 | 35992000 | 4846000000 |
| Friday, January 1, 2016 | 50714000 | 5062000000 |
| Sunday, January 1, 2017 | 71124000 | 4870000000 |
| Monday, January 1, 2018 | 114145000 | 5332000000 |
| Tuesday, January 1, 2019 | 132034000 | 5150000000 |
| Wednesday, January 1, 2020 | 149070000 | 5730000000 |
| Friday, January 1, 2021 | 121445000 | 5368000000 |
| Saturday, January 1, 2022 | 121673000 | 5414000000 |
| Sunday, January 1, 2023 | 119903000 | 6179000000 |
| Monday, January 1, 2024 | 156784000 | 7096000000 |
Cracking the code
In the ever-evolving landscape of biotechnology, cost management is pivotal. Over the past decade, Amgen Inc. and Agios Pharmaceuticals, Inc. have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amgen's SG&A expenses have consistently dwarfed those of Agios, reflecting its expansive operations and market reach. In 2023, Amgen's expenses peaked at approximately $6.2 billion, marking a 31% increase from 2014. In contrast, Agios, a smaller player, saw its SG&A expenses grow by over 500% during the same period, reaching around $120 million. This stark difference highlights the diverse financial strategies employed by large and small biotech firms. As the industry continues to innovate, understanding these financial dynamics offers valuable insights into the operational efficiencies and strategic priorities of these companies.
Breaking Down SG&A Expenses: Eli Lilly and Company vs Agios Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Amgen Inc. vs Sanofi
Operational Costs Compared: SG&A Analysis of Amgen Inc. and BioMarin Pharmaceutical Inc.
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Amgen Inc. or Galapagos NV
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Novavax, Inc.
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Pharming Group N.V. or Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Xenon Pharmaceuticals Inc. and Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Wave Life Sciences Ltd.
Selling, General, and Administrative Costs: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.